AI-generated analysis. Always verify with the original filing.
Lineage Cell Therapeutics, Inc. reported Q4 and full year 2025 financial results, including Q4 revenues of $6.6 million, net income of $0.9 million or $0.004 per share, and cash of $55.8 million as of December 31, 2025, expected to support operations into Q2 2028. Key highlights include achieving the first milestone under the Roche/Genentech collaboration for RG6501 (OpRegen) and positive 36-month Phase 1/2a study results.
Event Type
Disclosure
Mandatory
Variant
8-K
and in Exhibit 99.1 is being furnished and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press release issued March 5, 2026 104 Cover Page Interactive Data File (embedded
| Metric | Value | Basis |
|---|---|---|
| Revenues | $14.60 | |
| Operating Expenses | $51.20 | |
| R&D Expenses | $17.70 | |
| G&A Expenses | $18.50 | |
| Loss from Operations | $36.60 | |
| Net Loss | $63.50 | |
| Net Loss per Share | $0.28 |